Add this topic to your myFT Digest for news straight to your inbox
Swiss drugmaker’s generic business could have market capitalisation of $18bn-$25bn
Swiss group takes bold step to focus on faster-growing and higher-margin medicines
‘Pure pharma’ companies were the minority a decade ago but are now back in fashion
Shortages of antimalarials and inhalers feared as purchases spike
Sandoz reaches $195m criminal settlement with US DoJ related to four conspiracies
Richard Francis’s departure from Sandoz likely to spark speculation about its future
Swiss group in drive to focus on higher-margin innovative drugs
Sandoz worked with NHS on ‘copycat’ drug despite risk of no quick commercial return
Makers of medicines with $22bn sales a year expected to fight hard to delay rivals’ introduction
Retirement of founder Vasella poses questions for future strategy
Swiss drugs group’s chairman should not have accepted $78m payment
Claire Adler considers a trend toward cultural crossovers
International Edition